Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 5/20 | 0.63 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | DRD1 | P21728 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.40 |
| ▸ | LTA4H | P09960 | 2/20 | 0.38 |
| ▸ | TOP2A | P11388 | 1/20 | 0.38 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6742473 | 0.93 | ALOX15 (0.56) | ALOX15AKR1C3LTA4HTOP2A | |
| SCHEMBL6743519 | 0.87 | ALOX15 (0.68) | ALOX15ADRB2ADRA2ADRD2ADRA2C | |
| SCHEMBL6794712 | 0.86 | ALOX15 (0.72) | ALOX15ADRB2ADRA2ADRD2ADRA2C | |
| SCHEMBL6743545 | 0.84 | ALOX15 (0.47) | ALOX15AKR1C3TBK1LMNA | |
| SCHEMBL3616641 | 0.82 | ALOX15 (0.67) | ALOX15ADRB2ADRA2ADRD2ADRA2C | |
| SCHEMBL9404857 | 0.82 | ALOX15 (0.67) | ALOX15ADRB2ADRA2ADRD2ADRA2C | |
| SCHEMBL6790422 | 0.82 | ALOX15 (0.74) | ALOX15ADRB2ADRA2ADRD2ADRA2C | |
| Hydrochloric Acid SCHEMBL9404927 | 0.81 | ALOX15 (0.65) | ALOX15ADRB2ADRA2ADRD2ADRA2C | |
| SCHEMBL21976826 | 0.80 | ALOX15 (0.53) | ALOX15AKR1C3LTA4HTOP2A | |
| SCHEMBL6743505 | 0.80 | ALOX15 (0.59) | ALOX15AKR1C3LTA4HTOP2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122870-A1 | Treatment Of Ischemia-Reperfusion Injury | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2012-05-17 | — | — | US | disclosed |
| US-20100137315-A1 | Sphingosine Kinase Inhibitors and Methods of Their Use | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137315-A1 | Sphingosine Kinase Inhibitors and Methods of Their Use | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2010-06-03 | — | — | US | disclosed |
| US-20070032531-A1 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2007-02-08 | — | — | US | disclosed |
| US-20070032531-A1 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032531-A1 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | SPHK1, SPHK2, S1PR2 | ALOX15 622/4885ADRB2 2305/4885ADRA2A 2965/4885 |
| US-20120122870-A1 | Treatment Of Ischemia-Reperfusion Injury | SPHK1, SPHK2, S1PR2 | ALOX15 327/4885ADRB2 818/4885ADRA2A 904/4885 |
| US-20100137315-A1 | Sphingosine Kinase Inhibitors and Methods of Their Use | SPHK1, SPHK2, S1PR2 | ALOX15 598/4885ADRB2 2204/4885ADRA2A 2857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.